Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Lexiscan
Regadenoson is a selective A2A adenosine receptor agonist used in pharmacologic stress testing for patients unable to perform adequate exercise stress. It mimics the effects of adenosine by causing coronary vasodilation, increasing myocardial blood flow, and is useful in detecting coronary artery disease. It is administered intravenously and has a rapid onset and short half-life.
Used in pharmacologic stress testing for the diagnosis of coronary artery disease in patients unable to exercise adequately.
Outcome:
Increased risk of adverse cardiovascular events (e.g., hypotension, bradycardia, atrioventricular block).
Mechanism:
Additive vasodilatory effects.
Outcome:
May attenuate the vasodilatory effects of regadenoson.
Mechanism:
Opposing effects on heart rate and blood pressure.
Outcome:
Potential for reduced absorption of regadenoson.
Mechanism:
Changes in gastric pH.
Most likely new formulation: Improved delivery systems for enhanced patient comfort (Year: 2026, 30% confidence)
Based on current usage trends and clinical trial data, there is a low ( <5%) likelihood of any major regulatory changes regarding Regadenoson's approved indications in the next 2 years.
Coronary vasodilator, A2A adenosine receptor agonist
Adenosine analogue